Compass Pathways Plc (CMPS) reached a 52-week high of $15.42 on September 9, 2026, following progress in its lead candidate COMP360—a psilocybin-based therapy for treatment-resistant depression. The stock has surged 172% over the past year, reflecting growing confidence in regulatory approval and commercial potential. With a market capitalization of $2.11 billion and $433 million in cash reserves, the biotech firm remains well-positioned to fund operations through a potential product launch into 2028.
Compass Pathways Stock Rises to $15.42 on FDA Hope Amid Clinical Progress
Compass Pathways Plc’s shares hit a 52-week high as its psilocybin therapy candidate COMP360 advances toward FDA approval, supported by strong Phase 3 study results and analyst optimism.
PA
Priya Anand · Equities & Earnings Desk · 17 Sept 2026 · 22:35 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
